Argus Upgrades GlaxoSmithKline (GSK) to Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/14/2026
- Nasdaq ends sharply lower as hot inflation data stirs rate-hike worries
- Oil prices gain on attacks in Saudi Arabia, Iran's new tactics to target tankers
- U.S. consumer prices rise by 3.7% year-on-year in September
- Bank of America stock falls on earnings miss
- Netflix cuts 1,000 jobs as streaming giant seeks to boost engagement
Tweet
Share
E-mailGet Alerts GSK Hot Sheet
Price: $47.87 +3.46%
Rating Summary:
8 Buy, 14 Hold, 3 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 13 | Down: 12 | New: 90
Rating Summary:
8 Buy, 14 Hold, 3 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 13 | Down: 12 | New: 90
Join SI Premium – FREE
Argus upgraded GlaxoSmithKline (NYSE: GSK) from Hold to Buy.
For an analyst ratings summary and ratings history on GlaxoSmithKline click here. For more ratings news on GlaxoSmithKline click here.
Shares of GlaxoSmithKline closed at $55.30 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Vertical Research Partners Upgrades Lockheed Martin (LMT) to Buy, 'has some core franchises that are likely to prove resilient'
- BTIG Upgrades Liquidia Technologies (LQDA) to Buy
- Citi Upgrades AMMB Holdings Bhd (AMM:MK) (AMMHF) to Buy
Create E-mail Alert Related Categories
UpgradesRelated Entities
ArgusSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
